The estimated Net Worth of Brian C Stephenson is at least $11.4 Milion dollars as of 16 August 2024. Brian Stephenson owns over 25,797 units of BridgeBio Pharma Inc stock worth over $2,866,848 and over the last 5 years he sold BBIO stock worth over $6,155,426. In addition, he makes $2,347,120 as Chief Financial Officer at BridgeBio Pharma Inc.
Sign up
Brian Stephenson BBIO stock SEC Form 4 insiders trading
Brian has made over 33 trades of the BridgeBio Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 25,797 units of BBIO stock worth $722,058 on 16 August 2024.
The largest trade he's ever made was selling 64,929 units of BridgeBio Pharma Inc stock on 3 May 2023 worth over $920,693. On average, Brian trades about 19,336 units every 43 days since 2019. As of 16 August 2024 he still owns at least 102,424 units of BridgeBio Pharma Inc stock.
You can see the complete history of Brian Stephenson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Stephenson biography
Dr. Brian C. Stephenson Ph.D. serves as Chief Financial Officer of the Company. Prior to joining us, Dr. Stephenson served as Partner and the Head of Life Sciences for Capital IP Investment Partners, a special situation investment fund, from 2015 to 2018. From 2011 to 2014, Dr. Stephenson was a Director/Vice President Leerink Partners, an investment bank. Prior to that, Dr. Stephenson was an Engagement Manager at McKinsey & Company, a worldwide management consulting firm. He received his Ph.D. and M.S. degrees in chemical engineering from the Massachusetts Institute of Technology and his B.S. in chemical engineering from Brigham Young University. Dr. Stephenson is also a Chartered Financial Analyst charterholder.
What is the salary of Brian Stephenson?
As the Chief Financial Officer of BridgeBio Pharma Inc, the total compensation of Brian Stephenson at BridgeBio Pharma Inc is $2,347,120. There are 3 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
How old is Brian Stephenson?
Brian Stephenson is 39, he's been the Chief Financial Officer of BridgeBio Pharma Inc since 2018. There are 18 older and 4 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
What's Brian Stephenson's mailing address?
Brian's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Insiders trading at BridgeBio Pharma Inc
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo a Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
What does BridgeBio Pharma Inc do?
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
What does BridgeBio Pharma Inc's logo look like?
Complete history of Brian Stephenson stock trades at BridgeBio Pharma Inc
BridgeBio Pharma Inc executives and stock owners
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:
-
Neil Kumar,
Chief Executive Officer, Director -
Charles Homcy,
Chairman of Pharmaceuticals, Lead Director -
Uma Sinha,
Chief Scientific Officer -
Brian Stephenson,
Chief Financial Officer -
Eric Aguiar,
Independent Director -
Ali Satvat,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Neil Kumar Ph.D.,
Co-Founder, CEO & Director -
Dr. Brian C. Stephenson C.F.A., Ph.D.,
CFO, Sec. & Principal Accounting Officer -
James Momtazee,
Independent Director -
Richard Scheller,
Chairman of Research and Development, Director -
Dr. Michael Thomas Henderson M.D.,
Chief Bus. Officer -
Dr. Charles J. Homcy M.D.,
Chairman of Pharmaceuticals & Lead Director -
Dr. Richard H. Scheller Ph.D.,
Chairman of R&D and Director -
Dr. Cameron Turtle DPHIL, Ph.D.,
Chief Strategy Officer -
Randal Scott,
Independent Director -
Brenton Saunders,
Independent Director -
Andrew Lo,
Independent Director -
Ronald Daniels,
Independent Director -
Michael Henderson,
Chief Business Officer -
Cameron Turtle,
Senior Vice President - Portfolio Management and Corporate Development -
Frank Mccormick,
Chairman of Oncology -
Dr. Frank McCormick Ph.D.,
Chairman of Oncology -
Grace Rauh,
VP of Communications -
Dr. Uma Sinha Ph.D.,
Chief Scientific Officer -
Yi Ching Yau,
Chief Accounting Officer -
Genetic Disorder L.P.Kkr Ge...,
-
Management Holdings L.P.Kkr...,
-
Douglas A. Dachille,
-
Fred Hassan,
-
Global Performance Llc Viki...,
-
Global Investors Lp Viking ...,
-
Genetic Disorder L.P.Robert...,
-
Yi Ching Yau,
Chief Accounting Officer -
Brian M. Stolz,
Chief Operating Officer -
Hannah Valantine,
-
Brent L Saunders,
Director -
Andrea Ellis,
-
Global Investors Lp Viking ...,
-
Thomas Trimarchi,
President and COO